Loading data for ATTO — first visit, this takes a few seconds.

Attovia Therapeutics, Inc. (ATTO)

NasdaqGM: ATTO · 실시간 가격 · USD

22.15

+0.75 (3.50%)

종가 기준: Sep 01, 2026, 3:59 PM

알림

Alert

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

3.50% (1D)

매수호가	n/a
시가총액	943M
매출 (ttm)	1.35M
순이익 (ttm)	-64.1M
	0.00
	-2.5
	n/a
	-10.05
P/B (ttm)	-0.79
P/S (ttm)	698.35
실적 발표일	n/a

매도호가	n/a
거래량	147,440
평균 거래량 (20일)	519,947
시가	21.61
전일 종가	21.40
일중 범위	20.20 - 22.66
52주 범위	16.15 - 24.32
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

ATTO 소개

Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company's products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of chronic pruritic diseases such as CPUO, high-itch ...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Aug 5, 2026

직원 수 44

상장 거래소 NasdaqGM

티커 ATTO

웹사이트 https://www.attovia.com

전체 기업 정보

재무 실적

2025년 Attovia Therapeutics의 매출은 1.35M로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -60.63M로, 52.33% 증가했습니다.

재무제표

어닝 서프라이즈

Attovia Therapeutics가 Invalid Date에 분기 실적을 발표했습니다:

매출 n/a 예상치 하회 $0, 및 NaN% 전년 대비 성장.
EPS 예상치 하회 , 및 NaN% 전년 대비 성장.

주가가 움직인 이유

뉴스

1일 전 · MT Newswires

Attovia Therapeutics Could Serve as Key Player in Immunology, Inflammation, RBC Says

Attovia Therapeutics' (ATTO) ATTOBODY platform should position the company as a key player in immuno

1일 전 · The Fly

Deere upgraded, Lumentum initiated: Wall Street's top analyst calls

1일 전 · 24/7 Wall St.

Here Are Monday’s Top Wall Street Analyst Research Calls: AGCO Corporation, Deere & Co., Edison International, Lumentum Holdings, PG&E, Sempra Energy, STAG Industrial, Ticketplus, and More

Rate hike fears rattled markets heading into the Labor Day weekend, and Wall Street analysts responded with a flurry of bold calls on utilities, farm equipment giants, and a ticketing upstart that cou...

6일 전 · Trefis

Moderna Stock Carries A Market Value Its Revenue Does Not Support

Moderna's commercial business has shrunk and is lossmaking, which puts the weight of its market value on a pipeline rather than on revenue.

1주 전 · Trefis

Moderna Stock Had A Readout Waiting In Plain Sight

Before the melanoma result, the visible signs were an enrolled trial, a partner paying half its cost, and a market that had stopped pricing an unusually large move.

2 페이지 중 1

Attovia Therapeutics, Inc. (ATTO)